血管性血友病因子-糖蛋白Ⅰb轴与缺血性卒中

Von Willebrand factor-glycoproteinⅠb axis and ischemic stroke

由于传统再灌注治疗的时间窗较窄且存在再灌注损伤风险,故而从病理生理学角度对缺血性卒中的发病机制展开研究,探索减轻再灌注损伤的方法。文章阐述了血管性血友病因子(von Willebrand factor,vWF)与血小板糖蛋白(platelet glycoprotein,GP)Ⅰb的功能及其在止血、血栓形成和炎症中的作用,认为通过药物阻断vWF-GPⅠb的相互作用可能有助于缺血性卒中的治疗,并进一步讨论了其在缺血性卒中和缺血性脑损伤中的重要临床意义。

Due to the narrow time window of traditional reperfusion therapy and the presence of the risk of reperfusion injury,it is of great significance to study the pathogenesis of ischemic stroke and explore methods to reduce reperfusion injury from the perspective of pathophysiology.This article expounds the functions of von Willebrand factor(vWF)and platelet glycoprotein(GP)Ⅰb and their roles in hemostasis,thrombosis,and inflammation.It is believed that pharmacological blockade of the interaction of vWF-GPⅠb may contribute to the treatment of ischemic stroke.In addition,its clinical significance in ischemic stroke and ischemic brain injury was further discussed.